Evidence‐based guidelines for the use of immunologic tests: Anticentromere, Scl‐70, and nucleolar antibodies

Reveille, John D.; Solomon, Daniel H.

doi:10.1002/art.11113

Cited by 240 publications

(167 citation statements)

References 103 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…The estimated pooled prevalence of anti-RNAP III was 11% (95% CI 8-14%), in accordance with the estimation made by Koenig et al in their study of 4,672 patients from different countries (44). In comparison, prevalence of ACA was estimated at 26% in that same study, and at 33% in the 2003 American College of Rheumatology guidelines for antibody testing in SSc (45). Prevalence of anti-topo I was estimated at between 20 and 29% (44,45).…”

Section: Prevalence Of Anti-rnap III In Ssc 413supporting

confidence: 88%

“…In comparison, prevalence of ACA was estimated at 26% in that same study, and at 33% in the 2003 American College of Rheumatology guidelines for antibody testing in SSc (45). Prevalence of anti-topo I was estimated at between 20 and 29% (44,45). Antifibrillarin (U3 RNP) antibodies are found in 4-10% of SSc patients, anti-U1 RNP antibodies in 6%, anti-PM-Scl in 4-11%, and antiTh/To antibodies in 2-5% (18).…”

Section: Prevalence Of Anti-rnap III In Ssc 413mentioning

confidence: 88%

See 1 more Smart Citation

Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

Sobanski

Dauchet

Lefèvre

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. Studies assessing the prevalence of anti-RNA polymerase III (anti-RNAP III) antibodies in systemic sclerosis (SSc) have yielded a wide range of results. The aim of the present study was to describe a new SSc cohort tested for presence of anti-RNAP III and perform a systematic review and meta-analysis to assess the prevalence of anti-RNAP III in patients worldwide and the potential factors of variability.Methods. Seropositivity for anti-RNAP III was evaluated in a French cohort of SSc patients. A systematic review of the literature was carried out in PubMed and EMBase. Meta-analysis was performed using available data on prevalence, clinical characteristics of SSc patients, and the types of assays used for anti-RNAP III testing.Results. One hundred thirty-three French SSc patients were tested for anti-RNAP III, and a prevalence of 6-9% was found in these patients. Thirty studies representing a total population of 8,437 SSc patients were included in the meta-analysis. Prevalence of anti-RNAP III in this population was highly variable (range 0-41%). The overall pooled prevalence of anti-RNAP III was 11% (95% confidence interval 8-14), but heterogeneity was high among studies (I 2 ‫؍‬ 93%, P < 0.0001). Geographic factors such as continent or country of study origin partially explained this heterogeneity and correlated with the prevalence. No other baseline SSc characteristics were significantly correlated with the prevalence of anti-RNAP III.Conclusion. Data on our new cohort and our meta-analysis of the literature confirmed that anti-RNAP III prevalence in SSc varies among centers. Geographic factors were significantly associated with prevalence, which underscores the probable implication that genetic background and environmental factors play a role. Heterogeneity among studies remained largely unexplained.

show abstract

Section: Prevalence Of Anti-rnap III In Ssc 413supporting

confidence: 88%

Section: Prevalence Of Anti-rnap III In Ssc 413mentioning

confidence: 88%

Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

Sobanski

Dauchet

Lefèvre

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…Similarly, the features of digital fissuring ("mechanic hands") ( figure 1) and a fixed rash on the digital extensor surfaces (Gottron's sign) (figure 2) are hallmarks of the anti-synthetase syndrome or systemic sclerosis-myositis overlap associated with PM-Scl antibody positivity [16,[25][26][27][28][29][30][31][32]. The use of nailfold microscopy in the evaluation of individuals with Raynaud's phenomenon is encouraged as capillary loop abnormalities can be predictive of developing a CTD such as systemic sclerosis or dermatomyositis [33][34][35][36]. Inflammatory arthropathy is included as an IPAF criterion and is characterised by symptoms or signs of peripheral joint synovitis, but joint pain alone is not included due to its lack of specificity.…”

Section: Clinical Domainmentioning

confidence: 99%

“…Less specific serologic markers, such as low-titre antinuclear antibody (ANA), low-titre rheumatoid factor (RF), erythrocyte sedimentation rate, C-reactive protein or creatine phosphokinase, are not included. For ANA positivity with a diffuse, homogeneous or speckled staining pattern, a titre of at least 1:320 is required as this is consistent with most expert guidelines for ANA testing [36]. Low-titre ANA positivity with these staining patterns are excluded because weak ANA positivity is present in many non-rheumatic patients and even in "healthy" control populations, especially the elderly [36][37][38][39].…”

Section: Serologic Domainmentioning

confidence: 99%

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

et al. 2015

View full text Add to dashboard Cite

Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest an underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). Researchers have proposed differing criteria and terms to describe these patients, and lack of consensus over nomenclature and classification limits the ability to conduct prospective studies of a uniform cohort.The "European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease" was formed to create consensus regarding the nomenclature and classification criteria for patients with IIP and features of autoimmunity.The task force proposes the term "interstitial pneumonia with autoimmune features" (IPAF) and offers classification criteria organised around the presence of a combination of features from three domains: a clinical domain consisting of specific extra-thoracic features, a serologic domain consisting of specific autoantibodies, and a morphologic domain consisting of specific chest imaging, histopathologic or pulmonary physiologic features.A designation of IPAF should be used to identify individuals with IIP and features suggestive of, but not definitive for, a CTD. With IPAF, a sound platform has been provided from which to launch the requisite future research investigations of a more uniform cohort. @ERSpublications ERS/ATS task force provides nomenclature and classification criteria for patients with IIP and autoimmune features

show abstract

“…To date, 9 SSc-associated serum autoantibodies have been identified: anticentromere (ACA), anti-topoisomerase I (anti-topo I; anti-Scl-70), anti-RNA polymerase III (anti-RNAP III), anti-U1 RNP anti-Ku, anti-U11/U12 RNP (1-3), and 3 predominantly antinucleolar antibodies (anti-U3 RNP, anti-PM-Scl, and anti-Th/To). Each SSc patient typically is positive for only 1 of these SSc-related autoantibodies (4,5). The antibodies are recognized to correlate with disease manifestations and prognosis.…”

mentioning

confidence: 99%

Anti–U3 RNP autoantibodies in systemic sclerosis

Aggarwal

Lucas

Fertig

et al. 2009

Arthritis & Rheumatism

134

View full text Add to dashboard Cite

Objective. To describe the classification, demographic and clinical features, and survival in anti-U3 RNP autoantibody-positive patients with systemic sclerosis (SSc).Methods. Results. The anti-U3 RNP-positive group had a higher proportion of African American patients (27% versus 5%; P < 0.001) and male patients (29% versus 19%; P ‫؍‬ 0.021), and was younger at the time of first physician diagnosis (mean age 42.8 years versus 47.4 years; P ‫؍‬ 0.001). The 2 groups had similar proportions of patients with diffuse cutaneous involvement (47% and 45% in those with and those without anti-U3 RNP, respectively). However, among patients with diffuse cutaneous involvement, the mean maximum modified Rodnan skin score was significantly lower in the anti-U3 RNP group (22.3 versus 27.9; P < 0.001). Skeletal muscle involvement was more frequent in anti-U3 RNP-positive patients (25% versus 14%; P ‫؍‬ 0.002), as was "intrinsic" pulmonary arterial hypertension (PAH) (31% versus 13%; P < 0.001). The frequency of gastrointestinal involvement, cardiac involvement, pulmonary fibrosis, and "renal crisis" did not differ significantly between the 2 groups. Survival was worse in the anti-U3 RNP-positive group (hazard ratio 1.38 [95% confidence interval 1.05-1.82]). PAH was the most common known cause of death in patients with anti-U3 RNP (30%, versus 10% in the anti-U3 RNP-negative group; P < 0.001).Conclusion. The present findings demonstrate that the frequencies of African American race and male sex are greater among SSc patients with anti-U3 RNP antibody than those without, and the former group is younger at SSc diagnosis. Anti-U3 RNP-positive patients have more frequent skeletal muscle involvement and PAH, the latter being the most common cause of death.

show abstract

Evidence‐based guidelines for the use of immunologic tests: Anticentromere, Scl‐70, and nucleolar antibodies

Cited by 240 publications

References 103 publications

Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

Anti–U3 RNP autoantibodies in systemic sclerosis

Contact Info

Product

Resources

About